Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 randomized study of ramantamig + daratumumab versus investigator's choice of DVRd or DRd in newly diagnosed multiple myeloma not planned for upfront transplant
MOH_2026-07-06_016920Phase 3Not yet recruiting
- Sponsor
- Janssen Pharmaceutical
- Start
- Jul 2026
- Modality
- T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Trispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised trial of ramantamig in multiple myeloma (MM) (2 arms), sponsored by Janssen Pharmaceutical. Primary endpoints: Progression-free survival and Minimal residual disease negativity at 12 months. Planned start Jul 2026; status: not yet recruiting.
02
Drugs
ramantamig
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on MOH_2026-07-06_016920.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2026-07-06_016920.